Research Topics
| Gary R HudesSummaryAffiliation: Fox Chase Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Signaling inhibitors in the treatment of prostate cancerGary R Hudes
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Invest New Drugs 20:159-72. 2002....- Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinomaSteven J Cohen
Fox Chase Cancer Center, Philadelphia, PA 19111, USA
J Clin Oncol 21:1301-6. 2003..CONCLUSION: Although treatment with R115777 resulted in partial inhibition of FTase activity in mononuclear cells, it did not exhibit single-agent antitumor activity in patients with previously untreated metastatic pancreatic cancer... - Treatments for improving survival of patients with prostate cancerAlice K David
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Drugs Aging 20:683-99. 2003..Only the results of ongoing randomised trials can definitely establish that more patients with locally advanced and metastatic prostate cancer are living longer... 
Clinical trial experience with temsirolimus in patients with advanced renal cell carcinomaGary R Hudes
Genitourinary Malignancies Program, Fox Chase Cancer Center, 333 Cottman Ave, Philadelphia, PA 19111, USA
Semin Oncol 36:S26-36. 2009..Current trials are investigating the use of temsirolimus in sequence or in combination with other targeted agents to further improve outcomes...- Temsirolimus, interferon alfa, or both for advanced renal-cell carcinomaGary Hudes
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
N Engl J Med 356:2271-81. 2007..Interferon alfa is widely used for metastatic renal-cell carcinoma but has limited efficacy and tolerability. Temsirolimus, a specific inhibitor of the mammalian target of rapamycin kinase, may benefit patients with this disease... - Targeting mTOR in renal cell carcinomaGary R Hudes
Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
Cancer 115:2313-20. 2009..Laboratory studies indicate that these resistance mechanisms could be countered by using other targeted agents in combination with mTOR inhibitors... - Vinblastine and estramustine phosphate in metastatic renal cell carcinoma: a phase II trial of the Fox Chase NetworkNaomi B Haas
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Cancer 98:1837-41. 2003..Estramustine has been shown to potentiate the antimicrotubule effects of vinblastine. The authors sought to increase the activity of vinblastine in RCC through the addition of estramustine... - Impact of zoledronic acid on renal function in patients with cancer: Clinical significance and development of a predictive modelRaymond S McDermott
Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
J Support Oncol 4:524-9. 2006..75. The incidence of clinically significant renal deterioration in patients treated with zoledronic acid is low.We present a predictive model for decision support when estimating this risk... - mTOR as a target for therapy of renal cancerGary R Hudes
Genitourinary Malignancies Program, Fox Chase Cancer Center, Philadelphia, PA, USA
Clin Adv Hematol Oncol 5:772-4. 2007 
Serum amino acid levels as a biomarker for renal cell carcinomaAladdin Mustafa
Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
J Urol 186:1206-12. 2011..Therefore, we investigated whether serum amino acid profiles are a potentially useful biomarker in patients with renal cell carcinoma...- Weekly bryostatin-1 in metastatic renal cell carcinoma: a phase II studyNaomi B Haas
Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Clin Cancer Res 9:109-14. 2003..We conducted a Phase II trial of bryostatin-1, an inhibitor of protein kinase C, in advanced renal cell carcinoma to measure toxicity, response rate, time to progression, and induction of cytokines... - Global reactivation of epigenetically silenced genes in prostate cancerIlsiya Ibragimova
Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA
Cancer Prev Res (Phila) 3:1084-92. 2010..Further study of the hypermethylome will provide insight into the biology of the disease and facilitate translational studies in prostate cancer... - Combined classical cytogenetics and microarray-based genomic copy number analysis reveal frequent 3;5 rearrangements in clear cell renal cell carcinomaJianming Pei
Cancer Biology Program, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
Genes Chromosomes Cancer 49:610-9. 2010..These findings also suggest that the 5q duplication/3p deficiency resulting from unbalanced 3;5 translocations conveys a proliferative advantage of particular importance in ccRCC tumorigenesis... - Selecting targeted therapies for patients with renal cell carcinomaElizabeth R Plimack
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 2497, USA
J Natl Compr Canc Netw 9:997-1006; quiz 1007. 2011..These recommendations should supplement the current NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the treatment of advanced RCC... - Patient characteristics compete with dose as predictors of acute treatment toxicity in early phase clinical trialsAndre Rogatko
Departments of Biostatistics and Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Clin Cancer Res 10:4645-51. 2004..Mixed model ANOVA was used to model TI on the basis of data from all trials using a specific agent. Generalized estimating equations in the context of binary logistic regression were used to model dose-limiting toxicity... - Cranial nerve deficits in patients with metastatic prostate carcinoma: clinical features and treatment outcomesRaymond S McDermott
Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, USA
Cancer 101:1639-43. 2004..CONCLUSIONS: The authors concluded that palliative radiation therapy should be considered in this heterogeneous group of patients given the potential for significant symptom improvement...